According to filings with the U.S. Securities and Exchange Commission, Cytovia is raising $5,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Daniel Teper played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cytovia
Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer. Cytovia focuses on harnessing the innate immune system by developing complementary and disruptive NK-cell and NK-engager antibody platforms. We are developing three types of iPSC-derived Natural Killer cells: unedited iNK cells, TALEN gene-edited iNK cells with improved function and persistence, and TALEN gene-edited iNK cells with chimeric antigen receptors (CAR-iNKs) to improve tumor-specific targeting. The second complementary cornerstone technology is a quadrivalent multispecific antibody platform designed to engage natural killer cells by targeting NKp46 using a proprietary Flex-NK technology. These two technology platforms are being used to develop treatment of patients with solid tumors such as hepatocellular carcinoma (HCC) and glioblastoma as well as hematological malignancies such as refractory multiple myeloma. Clinical studies are expected to initiate in 2022.

To learn more about Cytovia, visit http://www.cytoviatx.com/

Contact:
Daniel Teper, Chief Executive Officer
786-591-7001
https://www.linkedin.com/in/danielteper/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.